secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-09-15T10:45:34+00:00
Accession:  0001193125-26-391280
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TRUTAKNA meets all endpoints in ORIGIN 3 final analysis; stabilizes eGFR, cuts progression risk 76%
--------------------------------------------------------------------------------

- Mean eGFR change at 52 weeks: TRUTAKNA -0.1 vs placebo -5.7 mL/min/1.73m² (treatment effect 5.6, p<0.0001).
- Annualized eGFR slope to 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/yr (effect 5.0, p<0.0001).
- Composite kidney progression events: 11 vs 38; HR 0.24 (95% CI 0.12-0.48), 76% risk reduction (p<0.0001).
- No dialysis/transplant/death events in TRUTAKNA arm vs 8 on placebo through 104 weeks; safety comparable to placebo.
- Over 350 patient start forms in first 10 weeks of launch; sBLA for full FDA approval planned Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/0001193125-26-391280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-391280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer